Vitest AG is a Swiss based medical biotechnology company with a corporate office in Germany, a subsidiary in South Africa and partnerships throughout the globe. Vitest AG focuses on sales, marketing and business development within the in-vitro diagnostic market and has positioned itself to play a significant role within the health care industry. Vitest AG markets a leading range of rapid diagnostic products which meet the highest standards globally in quality, accuracy, performance and stability, providing these products to markets worldwide.
The global market for in-vitro diagnostics (IVD) has been estimated by independent research groups to be in the region of $38 billion with the expectation of annual growth to be around 9%. With the diagnosis of patients representing on average 6% of total costs within a nation’s healthcare system, while directly influencing over 60% of total costs, the use of rapid tests provides an accurate and cost effective alternative to screening to obtain early diagnosis to facilitate both treatment and prevention of many diseases.
Rapid tests symbolize a key part to sustainable health solutions for the developing as well as the developed world’s fight against the spread of diseases whilst significantly reducing health care expenditures.
